Loading...

uniQure N.V.

QURENASDAQ
Healthcare
Biotechnology
$22.82
$1.66(7.84%)
U.S. Market opens in 1h 50m

uniQure N.V. Fundamental Analysis

uniQure N.V. (QURE) shows weak financial fundamentals with a PE ratio of -6.88, profit margin of -11.54%, and ROE of -1.46%. The company generates $0.0B in annual revenue with weak year-over-year growth of -40.64%.

Key Strengths

Cash Position40.93%
PEG Ratio-0.41
Current Ratio10.40

Areas of Concern

ROE-1.46%
Operating Margin-10.66%
We analyze QURE's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1030.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1030.6/100

We analyze QURE's fundamental strength across five key dimensions:

Efficiency Score

Weak

QURE struggles to generate sufficient returns from assets.

ROA > 10%
-26.82%

Valuation Score

Excellent

QURE trades at attractive valuation levels.

PE < 25
-6.88
PEG Ratio < 2
-0.41

Growth Score

Moderate

QURE shows steady but slowing expansion.

Revenue Growth > 5%
-40.64%
EPS Growth > 10%
29.67%

Financial Health Score

Excellent

QURE maintains a strong and stable balance sheet.

Debt/Equity < 1
0.42
Current Ratio > 1
10.40

Profitability Score

Weak

QURE struggles to sustain strong margins.

ROE > 15%
-145.81%
Net Margin ≥ 15%
-11.54%
Positive Free Cash Flow
No

Key Financial Metrics

Is QURE Expensive or Cheap?

P/E Ratio

QURE trades at -6.88 times earnings. This suggests potential undervaluation.

-6.88

PEG Ratio

When adjusting for growth, QURE's PEG of -0.41 indicates potential undervaluation.

-0.41

Price to Book

The market values uniQure N.V. at 9.63 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

9.63

EV/EBITDA

Enterprise value stands at -9.05 times EBITDA. This is generally considered low.

-9.05

How Well Does QURE Make Money?

Net Profit Margin

For every $100 in sales, uniQure N.V. keeps $-11.54 as profit after all expenses.

-11.54%

Operating Margin

Core operations generate -10.66 in profit for every $100 in revenue, before interest and taxes.

-10.66%

ROE

Management delivers $-1.46 in profit for every $100 of shareholder equity.

-1.46%

ROA

uniQure N.V. generates $-26.82 in profit for every $100 in assets, demonstrating efficient asset deployment.

-26.82%

Following the Money - Real Cash Generation

Operating Cash Flow

uniQure N.V. generates limited operating cash flow of $-168.98M, signaling weaker underlying cash strength.

$-168.98M

Free Cash Flow

uniQure N.V. generates weak or negative free cash flow of $-169.00M, restricting financial flexibility.

$-169.00M

FCF Per Share

Each share generates $-2.74 in free cash annually.

$-2.74

FCF Yield

QURE converts -12.24% of its market value into free cash.

-12.24%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-6.88

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.41

vs 25 benchmark

P/B Ratio

Price to book value ratio

9.63

vs 25 benchmark

P/S Ratio

Price to sales ratio

78.02

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.42

vs 25 benchmark

Current Ratio

Current assets to current liabilities

10.40

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.46

vs 25 benchmark

ROA

Return on assets percentage

-0.27

vs 25 benchmark

ROCE

Return on capital employed

-0.27

vs 25 benchmark

How QURE Stacks Against Its Sector Peers

MetricQURE ValueSector AveragePerformance
P/E Ratio-6.8829.77 Better (Cheaper)
ROE-145.81%682.00% Weak
Net Margin-1154.42%-45016.00% (disorted) Weak
Debt/Equity0.420.42 Neutral
Current Ratio10.404.49 Strong Liquidity
ROA-26.82%-16121.00% (disorted) Weak

QURE outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews uniQure N.V.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-66.82%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-23.07%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-2.07%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ